Compared to Estimates, OrthoPediatrics (KIDS) Q4 Earnings: A Look at Key Metrics

For the quarter ended December 2024, OrthoPediatrics (KIDS) reported revenue of $52.67 million, up 40% over the same period last year. EPS came in at -$0.29, compared to -$0.23 in the year-ago quarter.The reported revenue represents a surprise of -0.06% over the Zacks Consensus Estimate of $52.7 million. With the consensus EPS estimate being -$0.22, the EPS surprise was -31.82%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how OrthoPediatrics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Product sales by category- Trauma and deformity: $36.41 million versus the three-analyst average estimate of $35.25 million. The reported number represents a year-over-year change of +34.5%. Product sales by category- Sports medicine/other: $0.63 million compared to the $1.12 million average estimate based on three analysts. The reported number represents a change of -29.2% year over year. Product sales by category- Scoliosis: $15.63 million versus $12.86 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +61.8% change. View all Key Company Metrics for OrthoPediatrics here>>>Shares of OrthoPediatrics have returned -3.7% over the past month versus the Zacks S&P 500 composite's -2.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report OrthoPediatrics Corp. (KIDS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks